Analyst Price Targets — BDSX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 19, 2025 11:45 am | — | Canaccord Genuity | $20.00 | $6.69 | TheFly | Biodesix price target lowered to $20 from $30 at Canaccord |
| September 16, 2024 9:03 am | Sung Ji Nam | Scotiabank | $3.00 | $1.82 | TheFly | Biodesix initiated with an Outperform at Scotiabank |
| July 26, 2024 7:17 am | Bill Bonello | Craig-Hallum | $3.00 | $1.68 | StreetInsider | Craig-Hallum Starts Biodesix (BDSX) at Buy |
Latest News for BDSX
Biodesix, Inc. (NASDAQ: BDSX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six analysts that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12-month price objective among
The mean of analysts' price targets for Biodesix (BDSX) points to an 111.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here is how Biodesix, Inc. (BDSX) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
Biodesix, Inc. (BDSX) Q4 2025 Earnings Call Transcript
Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $1.2 per share a year ago.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BDSX.
U.S. House Trading
No House trades found for BDSX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.